GLP-1 drugs show dental links

Amber M. Nehme wrote in *Dimensions of Dental Hygiene* on August 4 that GLP-1 receptor agonists are starting to show up in dental care as more patients use semaglutide and tirzepatide for diabetes and obesity. Her article said emerging research points to possible periodontal benefits tied to lower systemic inflammation, while dentists are also being told to watch for oral side effects and document medication histories closely. That mix of promise and caution is arriving as access broadens: the FDA approved oral semaglutide for weight loss in December 2025, and CVS Health expanded its GLP-1 access program on August 5. ### Why are dentists paying attention to GLP-1 drugs now? Novo Nordisk’s oral semaglutide, sold as Wegovy, became the first oral GLP-1 pill approved for weight loss on December 22, 2025, according to AJMC. Novo said it planned a U.S. launch in early January 2026, adding a once-daily pill to a market previously dominated by injections. CVS Health said on August 5 that it revamped its weight-management program so eligible adults can connect with clinicians through MinuteClinic, identify savings options and pick up GLP-1 medicines at about 9,000 CVS Pharmacy locations. (dimensionsofdentalhygiene.com) CVS also said its collaboration with Eli Lilly would give eligible Zepbound and Foundayo patients another access point through the CVS Health app. (ajmc.com) ### What is the periodontal upside researchers are discussing? Nehme reported on August 4 that GLP-1 drugs may help periodontal health by reducing systemic inflammation, a central driver of periodontal disease. Her article said patients with obesity and poorly controlled diabetes often have higher inflammatory markers and worse periodontal outcomes, raising the possibility that better metabolic control could improve gum health as well. (cvshealth.com) A July 9 review in the *Journal of Clinical Medicine* said preclinical and limited clinical evidence suggests GLP-1 receptor agonists may attenuate periodontal inflammation, though effects on alveolar bone remain uncertain. The review said human oral-health-endpoint data are still scarce and much of the evidence is indirect, preclinical or drawn from case reports and pharmacovigilance data. ### What oral problems are clinicians being told to watch for? (dimensionsofdentalhygiene.com) The July 9 review said gastrointestinal side effects, reduced fluid intake and possible salivary changes may contribute to complaints often labeled “Ozempic mouth,” “Ozempic teeth” and “Ozempic breath.” The authors said those reports sit alongside broader tolerability issues such as nausea, vomiting and belching that can have dental consequences, including dry mouth and erosion risk. (mdpi.com) The same review said dental practitioners should “proactively manage” oral consequences and called for validated oral-health endpoints in future incretin trials. Nehme’s article similarly said oral health professionals are in position to identify medication use and monitor side effects as GLP-1 exposure rises in routine practice. ### What about the eye-safety signals mentioned in recent coverage? ScienceAlert reported on August 5 that a study in *Diabetes, Obesity and Metabolism* found GLP-1 drugs were associated with a lower risk of age-related macular degeneration in more than 157,000 matched patients age 60 and older with obesity but not diabetes. (mdpi.com) The report said GLP-1 use was linked to an estimated 18% lower risk of developing AMD over follow-up, with no clear association for wet AMD. Johns Hopkins Medicine said on July 17 that a separate federally funded study of adults with type 2 diabetes found semaglutide and other GLP-1 drugs did not statistically increase or decrease the risk of neovascular age-related macular degeneration. Cindy Cai, the study’s principal investigator, said prior research had pointed in both directions. (sciencealert.com) ### What is the practical takeaway for dental offices? The July 9 review said the oral cavity is a plausible direct target of incretin therapy and a practical site for monitoring tolerability. That means dentists and hygienists are likely to see more patients taking GLP-1 drugs, ask more often about current medications, and track symptoms such as xerostomia, vomiting history and changes in oral hygiene tolerance. (hopkinsmedicine.org) CVS Health’s August 5 expansion and the January 2026 launch of oral Wegovy provide the next markers to watch as access grows. Future evidence is likely to come from journal studies and pharmacovigilance reports that test whether the periodontal signal holds up in larger human datasets. (cvshealth.com) (mdpi.com)